Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy...

Source: Journal of Hematology and Oncology - August 3, 2023 Category: Hematology Authors: Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo and Yongping Song Tags: Correspondence Source Type: research